Amgen and Allergan announced on Thursday that the European Commission has granted a marketing authorization to Mvasi, a biosimilar bevacizumab referencing Avastin, for the treatment of certain cancers.
Amgen and Allergan announced on Thursday that the European Commission (EC) has granted a marketing authorization to Mvasi, a biosimilar bevacizumab referencing Avastin, for the treatment of certain cancers.
The EC approval grants a centralized marketing authorization for the drug, with unified labeling, in the 28 members of the European Union. European Economic Area nations (Norway, Iceland, and Liechtenstein) will make regulatory decisions concerning the drug based on the EC’s approval. The marketing authorization follows a positive opinion on the biosimilar granted by the European Medicines Agency’s Committee for Medicinal Products for Human Use granted in November 2017.
"The European Commission's approval of Mvasi marks a significant milestone for both Amgen and the oncology community, providing a biosimilar for a medicine which is used across multiple types of cancer," said Sean E. Harper, MD, executive vice president of research and development at Amgen, in a statement. "Mvasi is the first targeted cancer biosimilar from Amgen's portfolio approved in Europe, underscoring our commitment to delivering high-quality medicines that address some of the most serious illnesses."
European regulatory clearance for Mvasi follows the FDA’s approval of the drug in September 2017, based on a comprehensive data package including analytical, pharmacokinetic, and clinical data that demonstrated that the biosimilar and its reference are highly similar, with no clinically meaningful differences in terms of efficacy, safety, and immunogenicity. Clinical data presented to the FDA included results of a phase 3 study of Mvasi in patients with non—small-cell lung cancer.
Despite these 2 approvals, the timing of Mvasi’s launch remains unclear. In the United States, ongoing patent litigation continues to delay commercial availability of the biosimilar; Genentech, maker of the reference Avastin, recently sued Amgen over Mvasi in a Delaware court, saying that the biosimilar developer did not properly exchange information related to the drug as required under the Biologics Price Competition and Innovation Act, and that Amgen refused to negotiate the scope of litigation concerning alleged patent infringement. Meanwhile, Amgen has filed suit in a California court, seeking a judgment that Mvasi did not and will not infringe on 27 patents covering the reference Avastin.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international regognition procedure under the Medicines and Healthcare products Regulatory Agency (MHRA) could expand biosimilar access within the United kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.